Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 1 […]
More Stories
Wall Street Zen Downgrades Ingram Micro (NYSE:INGM) to Hold
Ingram Micro (NYSE:INGM – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating...
Reviewing Baxter International (NYSE:BAX) and INLIF (NASDAQ:INLF)
Baxter International (NYSE:BAX – Get Free Report) and INLIF (NASDAQ:INLF – Get Free Report) are both medical companies, but which...
Interactive Strength (NASDAQ:TRNR) Raised to Hold at Wall Street Zen
Interactive Strength (NASDAQ:TRNR – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating...
Wall Street Zen Downgrades DeFi Development (NASDAQ:DFDV) to Sell
DeFi Development (NASDAQ:DFDV – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating...
CG Oncology (NASDAQ:CGON) Stock Rating Lowered by Wall Street Zen
CG Oncology (NASDAQ:CGON – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating...
Maplebear (NASDAQ:CART) Raised to “Buy” at Wall Street Zen
Maplebear (NASDAQ:CART – Get Free Report) was upgraded by analysts at Wall Street Zen from a “hold” rating to a...